Allogene Therapeutics (ALLO) Peer Comparison
$0.64
As on 20-Nov-2026 12:33EST
Market cap
$291 Mln
Revenue (TTM)
$5 Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
| Allogene Therapeutics (ALLO) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
291 | 18,292 | 18,064 | 16,837 | 11,432 |
Revenue ($ Mln) |
5 | 2,838 | 1,208 | 2,497 | 1,802 |
Net Profit ($ Mln) |
-174.46 | 517.83 | 890.37 | 885.14 | 485.42 |
Net Margin (%) |
-3,759.98 | 18.24 | 73.69 | 35.45 | 26.93 |
RoE (%) |
-51.97 | 87.53 | 88.40 | 46.96 | -- |
Price to Earnings |
-- | 36.31 | 18.11 | 20.66 | 25.19 |
Price-To-Book |
0.73 | 31.41 | 10.44 | 9.18 | 97.15 |
Income Statement ($ Mln)
| Allogene Therapeutics (ALLO) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
4.64 | 2,838.39 | 1,208.20 | 2,496.86 | 1,802.45 |
|
Cost of Revenue
|
5.93 | 2,011.22 | 113.42 | 93.32 | 319.65 |
|
Gross Profit
|
-12.36 | 760.62 | 588.53 | 2,236.43 | 1,167.84 |
|
Operating Expenses
|
194.85 | 220.03 | 872.49 | 1,400.14 | 474.96 |
|
Operating Profit (EBIT)
|
-190.21 | 607.14 | 222.29 | 1,003.39 | 1,007.84 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
-174.46 | 626.99 | 271.18 | 1,065.84 | 655.01 |
|
Provision for Tax
|
0.00 | 109.17 | -619.19 | 180.70 | 169.59 |
|
Profit after Tax (Net Income)
|
-174.46 | 517.83 | 890.37 | 885.14 | 485.42 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Allogene Therapeutics (ALLO) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
392.55 | 584.94 | 1,525.85 | 1,833.83 | -55.24 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
80.27 | 221.56 | 384.05 | 267.78 | 3,052.50 |
|
Current Liabilities
|
38.50 | 1,496.10 | 558.37 | 411.88 | 476.09 |
|
Total Liabilities
|
415.91 | 1,975.47 | 1,302.02 | 2,844.42 | 2,525.32 |
Assets ($ Mln)
| Allogene Therapeutics (ALLO) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
211.49 | 1,057.60 | 854.45 | 1,191.87 | 1,626.62 |
|
Current Assets
|
299.83 | 1,245.00 | 1,613.82 | 1,321.62 | 1,846.73 |
|
Total Assets
|
415.91 | 1,975.47 | 1,302.02 | 2,844.42 | 2,525.32 |
|
Total Debt*
|
68.04 | 146.04 | 455.38 | 162.20 | 3,250.30 |
|
Net Current Assets
|
261.33 | -251.10 | 1,037.87 | 909.75 | 1,370.64 |
Cashflow ($ Mln)
| Allogene Therapeutics (ALLO) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-149.25 | 713.22 | 51.77 | 884.27 | 651.56 |
|
Cash Flow from Investing Activities
|
95.56 | -31.14 | -8.15 | 350.44 | -545.81 |
|
Cash from Financing Activities
|
30.16 | -860.39 | 34.89 | -969.59 | -85.17 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Allogene Therapeutics (ALLO) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-42.96 | 57.43 | -30.01 | 32.82 | 15.61 |
|
ROE (%)
|
-51.97 | 87.53 | 88.40 | 46.96 | 153.59 |
|
ROA (%)
|
-34.16 | 15.15 | 34.34 | 28.91 | 13.85 |
|
EBIT Margin (%)
|
-3,731.21 | 21.70 | 20.00 | 42.02 | 37.56 |
|
Net Margin (%)
|
-3,759.98 | 18.24 | 73.69 | 35.45 | 26.93 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Allogene Therapeutics (ALLO) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
21,190.91 | 20.35 | 86.87 | 9.12 | 45.03 |
|
EBIT Growth (%)
|
17.84 | 18.61 | 260.53 | 23.13 | -11.34 |
|
Net Profit Growth (%)
|
17.71 | 19.59 | 482.23 | 30.57 | -18.48 |
|
EPS Growth (%)
|
35.94 | 28.28 | 453.25 | 38.78 | -17.34 |
|
Book Value Growth (%)
|
-20.13 | 108.60 | 878.06 | -7.57 | -110.94 |
Valuation Ratios
| Allogene Therapeutics (ALLO) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-1.58 | 36.06 | -59.76 | 15.79 | 24.99 |
|
Price / Book Value
|
1.03 | 35.44 | -80.42 | 5.72 | 162.23 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-0.76 | 27.88 | -121.54 | 12.44 | 17.31 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Allogene Therapeutics (ALLO) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.25 | 0.00 | -53.31 |
|
Short term debt to equity ratio
|
0.00 | 0.00 | 0.05 | 0.00 | -5.53 |
|
Current Ratio
|
7.79 | 0.83 | 2.89 | 3.21 | 3.88 |
|
Quick Ratio
|
7.79 | 0.83 | 2.29 | 3.14 | 3.60 |
|
Interest Coverage
|
-129.68 | -- | 2.74 | -- | 30.70 |
Operating Efficiency Ratios
| Allogene Therapeutics (ALLO) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
0.00 | 15.77 | 21.41 | 13.16 | 29.16 |
|
Asset Turnover
|
0.01 | 0.83 | 0.47 | 0.82 | 0.51 |
|
Receivable days
|
-- | 50.42 | 85.52 | 43.48 | 98.04 |
|
Inventory Days
|
-- | -- | 1,056.70 | 96.17 | 254.12 |
|
Payable days
|
142.80 | 6.26 | 331.01 | 147.97 | 24.86 |
|
Cash Conversion Cycle
|
-- | -- | 811.21 | -8.32 | 327.29 |